Candidatures for WinningNormandy research training network

Our laboratory is welcoming applications from ambitious junior researchers with at least 4 years of research experience (including PhD studies) to apply for the competitive research funding from the postdoctoral research training network  The WINNINGNormandy Fellowship Programme | Région Normandie

Our laboratory is offering potential candidates a unique research environment, including  long-standing expertise in functional in vivo and ex vivo cardiovascular evaluations and access to our wide panel of relevant experimental models of cardiovascular diseases ranging from myocardial infarction, ischemia-reperfusion injury, chronic heart failure, acute heart failure, metabolic syndrome-induced cardiomyopathy, chronic kidney-disease induced cardiomyopathy, and sepsis-induced cardiomyopathy. Please contact our lead PIs for more details:

Paulus Mulder (expertise in HF models) paul.mulder[at]univ-rouen.fr ORCID

Ebba Brakenhielm (expertise in cardiac lymphatics) ebba.brakenhielm[at]univ-rouen.fr ORCID

Jeremy Bellien (expertise in endothelial dysfunction) jeremy.bellien[at]univ-rouen.fr ORCID

Offres de financement de thèse 2021

Nous avons pour la rentrée 2021 quatres potentielles offres de financements de thèse dans le laboratoire:

  • Rôle de molécules de co-signalisation immunitaire lymphatiques en immuno-onco-cardiologie : myocardites induites par les inhibiteurs des points de contrôle immunitaires. 
  • Impact délétère des particules d'usure des freins dans le syndrome métabolique. 
  • Un Traitement par un Antagoniste du récepteur minéralocorticoïde permet-t-il de limiter une aGgravation de l’Insuffisance Cardiaque à fraction d’éjection préservée suite à l’Ovariectomie de souris en Syndrome Métabolique ? (TRAGICO-SMet).
  •  Lactate de Sodium au cours du sepsis : (LactMet-Heart) impact métabolique sur la dysfonction cardio-vasculaire

voir plus

Finerenone beneficial impact in ovariectomized mice

A recent study, directed by A Ouvrard-Pascaud, published in ESC Heart Failure describes the beneficial impact of Mineralocorticoid receptor blockade, with finerenone, on cardiac function and exercise capacity in ovariectomized mice. Briefly, the authors evaluated whether the non-steroidal mineralocorticoid receptor antagonist finerenone limited the progression of heart failure in ovariectomized (OVX) mice with metabolic disorders. They found that Finerenone improved mitochondrial ATP production in OVX mice. In addition, weight gain, increased blood pressure, and decreased insulin and glucose tolerance developing in OVX mice were improved by finerenone. The exercise capacity was diminished in untreated OVX mice and improved with Finerenone.

sEH blockade prevents cardiorenal syndrome

A recent experimental study, directed by D Guerrout, published in Front Mol Biosci , describes the beneficial cardiac impact, on both diastolic and systolic functions, of blocking soluble epoxide hydrolase (sEH) during chronic kidney disease (CKD) induced by 5/6 nephrectomy (Nx) in mice. These beneficial effects may be mediated by the prevention of endothelial dysfunction, independent from kidney preservation and antihypertensor effect. Thus, inhibition of sEH holds a therapeutic potential in preventing type 4 cardiorenal syndrome.

More Articles ...

INSERM U1096

Endothelium, Valvulopathy
& Heart Failure

Réalisation Internet Bordeaux LOGO internet bordeaux mini

Contact Us

Legal mentions